During the past decade, Klinische Forschung Hamburg GmbH conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 17 clinical trials were completed, i.e. on average, 85% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 10 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinische Forschung Hamburg GmbH" #1 sponsor was "Pfizer" with 12 trials, followed by "Kowa Research Europe" with 4 trials sponsored, "Idorsia Pharmaceuticals Ltd." with 2 trials sponsored, "UNION therapeutics" with 2 trials sponsored and "Allergan" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinische Forschung Hamburg GmbH" #1 collaborator was "Biofortis Mérieux NutriSciences" with 1 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Labor Dr. Spranger (Central lab)" with 1 trials as a collaborator and "Laboratorios LETI SL (Study Medication)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Klinische Forschung Hamburg GmbH" are "Psoriasis" (5 trials), "Smoking Cessation" (4 trials), "Dermatitis, Atopic" (3 trials), "Depressive Disorder, Major" (2 trials) and "Dyslipidemia" (2 trials). Many other conditions were trialed in "Klinische Forschung Hamburg GmbH" in a lesser frequency.

Most popular intervention types in "Klinische Forschung Hamburg GmbH" are "Drug" (30 trials), "Biological" (7 trials), "Other" (4 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Pitavastatin" (4 trials), "placebo" (3 trials), "CP-690,550" (2 trials) and "Daridorexant 25 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinische Forschung Hamburg GmbH" are 35 trials for "All" genders.

Currently, there are NaN active trials in "Klinische Forschung Hamburg GmbH". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Klinische Forschung Hamburg GmbH, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Klinische Forschung Hamburg GmbH, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 1 trials that are defined as “Not Applicable".